GlassScriptPhysician profile
Caitlin M Brooks
NPI 1659701050
$7,662.89
in general payments reported to CMS, 2019-2025
15 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,332 · 2022: $715 · 2023: $4,316 · 2024: $688 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,963 · Food and Beverage: $2,373 · Education: $162 · Travel and Lodging: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,962.50 |
| Food and Beverage | $2,373.02 |
| Education | $162.48 |
| Travel and Lodging | $118.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,168.08 | 2022-2023 | Perseris |
| Neurocrine Biosciences, INC. | $1,191.01 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $886.80 | 2021-2025 | Caplyta |
| Alkermes, INC. | $702.73 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $405.42 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $381.75 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $376.38 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $234.16 | 2022-2025 | Invega Sustenna, Spravato |
| Gilead Sciences, INC. | $90.00 | 2022 | |
| Lundbeck LLC | $74.29 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $44.64 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $33.37 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $27.55 | 2024 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.